Mackenzie Financial Corp Increases Position in Boston Scientific Corporation $BSX

Mackenzie Financial Corp grew its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 93.5% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 3,103,508 shares of the medical equipment provider’s stock after buying an additional 1,499,897 shares during the period. Mackenzie Financial Corp owned 0.21% of Boston Scientific worth $302,995,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Gerber Kawasaki Wealth & Investment Management boosted its stake in Boston Scientific by 3.8% during the 2nd quarter. Gerber Kawasaki Wealth & Investment Management now owns 2,711 shares of the medical equipment provider’s stock valued at $291,000 after acquiring an additional 99 shares during the last quarter. Crown Wealth Group LLC increased its stake in Boston Scientific by 4.7% during the 3rd quarter. Crown Wealth Group LLC now owns 2,238 shares of the medical equipment provider’s stock valued at $218,000 after buying an additional 100 shares during the period. Claret Asset Management Corp raised its holdings in Boston Scientific by 4.4% during the third quarter. Claret Asset Management Corp now owns 2,400 shares of the medical equipment provider’s stock worth $234,000 after purchasing an additional 102 shares in the last quarter. Sound View Wealth Advisors Group LLC lifted its holdings in shares of Boston Scientific by 3.9% in the second quarter. Sound View Wealth Advisors Group LLC now owns 2,738 shares of the medical equipment provider’s stock valued at $294,000 after buying an additional 103 shares during the period. Finally, Cary Street Partners Investment Advisory LLC boosted its position in shares of Boston Scientific by 5.1% during the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 2,106 shares of the medical equipment provider’s stock valued at $206,000 after purchasing an additional 103 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Negative Sentiment: Investor alert from TMCNet flags a securities‑fraud lawsuit and solicits investors to consider leading the class action. BSX Investor Alert: BOSTON SCIENTIFIC CORPORATION Securities Fraud Lawsuit
• Negative Sentiment: Bragar Eagel & Squire announces an investigation on behalf of long‑term BSX shareholders and invites contact regarding losses. BOSTON SCIENTIFIC ALERT: Bragar Eagel & Squire
• Negative Sentiment: Rosen Law Firm public notice: a class action was filed covering the same class period and warns investors to secure counsel before the May 4 deadline. ROSEN Encourages Boston Scientific Investors to Secure Counsel
• Negative Sentiment: Robbins Geller Rudman & Dowd notifies investors of opportunity to seek lead‑plaintiff status in the filed class action (same class period). INVESTOR ALERT: RGRD Law
• Negative Sentiment: Faruqi & Faruqi issues a reminder about the May 4, 2026 deadline for investors to seek lead‑plaintiff appointment in the securities class action. Faruqi & Faruqi Reminder
• Negative Sentiment: Law Offices of Frank R. Cruz encourages BSX shareholders to inquire about a securities fraud class action — another solicitor notice piling on legal attention. Frank R. Cruz Notice
• Negative Sentiment: The Gross Law Firm posts a shareholder notice about a class action and the May 4 deadline to join as a plaintiff. Gross Law Firm Notice
• Negative Sentiment: Portnoy Law Firm announces a class action for investors who bought BSX during the stated class period and highlights the lead‑plaintiff deadline. Portnoy Law Firm Announcement
• Negative Sentiment: Bernstein Liebhard issues a shareholder alert confirming a securities‑fraud class action has been filed against Boston Scientific. Bernstein Liebhard Alert
• Negative Sentiment: Levi & Korsinsky notifies shareholders about the class action and encourages contact before the May 4 deadline. Levi & Korsinsky Notice
• Negative Sentiment: Robbins LLP issues a class action notice covering the same class period and urging investor contact. Robbins LLP Notice
• Negative Sentiment: Unusual options activity: traders bought ~23,040 put contracts on Monday (≈27% above typical put volume), signaling increased bearish positioning or hedging demand. Options Activity Report

Analyst Ratings Changes

A number of equities analysts recently issued reports on BSX shares. Sanford C. Bernstein restated an “outperform” rating and issued a $112.00 target price on shares of Boston Scientific in a report on Friday, February 6th. Wells Fargo & Company decreased their target price on shares of Boston Scientific from $125.00 to $94.00 and set an “overweight” rating for the company in a report on Thursday, February 5th. Robert W. Baird dropped their target price on shares of Boston Scientific from $118.00 to $101.00 and set an “outperform” rating on the stock in a research report on Thursday, February 5th. Royal Bank Of Canada cut their price target on shares of Boston Scientific from $130.00 to $115.00 and set an “outperform” rating on the stock in a report on Thursday, February 5th. Finally, Citigroup cut their target price on shares of Boston Scientific from $130.00 to $102.00 and set a “buy” rating on the stock in a research note on Thursday, February 5th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, Boston Scientific presently has an average rating of “Moderate Buy” and an average price target of $108.36.

Boston Scientific Stock Down 2.8%

BSX stock opened at $69.90 on Wednesday. The company has a current ratio of 1.62, a quick ratio of 1.08 and a debt-to-equity ratio of 0.46. Boston Scientific Corporation has a 1 year low of $69.52 and a 1 year high of $109.50. The company has a fifty day simple moving average of $84.03 and a 200 day simple moving average of $93.98. The firm has a market cap of $103.72 billion, a PE ratio of 36.03, a PEG ratio of 1.01 and a beta of 0.69.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, topping the consensus estimate of $0.78 by $0.02. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The firm had revenue of $5.29 billion for the quarter, compared to the consensus estimate of $5.29 billion. During the same period in the prior year, the business posted $0.70 earnings per share. The business’s quarterly revenue was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Sell-side analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Insider Buying and Selling at Boston Scientific

In other news, CEO Michael F. Mahoney sold 160,901 shares of the business’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the sale, the chief executive officer directly owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. The trade was a 10.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 0.50% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.